Bringing you the Best Analytical Legal News
Members of the Bar/Parties-in-Person have been advised avail hybrid mode of appearance through video conferencing facility in their matters listed before the Courts.
Continue reading
Cyril Amarchand Mangaldas (“CAM”) represented KKR in KKR’s fresh investment in Lighthouse Learning Private Limited, a leading Indian education services provider. The
Continue reading
The transaction strengthens Lighthouse Learning’s position as a leading Indian education services provider. CAM advised on corporate, diligence, real estate, employment, disputes, finance, and competition aspects of the deal.
Continue reading
The India International Arbitration Centre launched its magazine titled “The Equilibrium”.
Continue reading
The deal forms part of Wakefit’s broader pre-IPO fundraising ahead of its proposed public listing. SAM advised on transaction, regulatory and tax aspects.
Continue reading
SAM advised Meesho on the fresh issue, offer for sale, and securities regulatory aspects through a multidisciplinary capital markets team.
Continue reading
SAM supported the transaction end-to-end, including structuring, diligence, competition, and regulatory aspects. The deal involved multi-team coordination across M&A, private equity, competition, and regulatory practices.
Continue reading
Shardul Amarchand Mangaldas advised Biocon Limited on its ~USD 1.2 billion integration involving acquisition of minority stakes in Biocon Biologics from multiple investors.
Continue reading
The transaction marks the first phase of consolidating L&T’s real estate assets into a unified entity positioned for India’s growing property market.
Continue reading
The firm advised prominent investors such as Elevation Capital, Peak Investments, Venture Highway, and Y Combinator. The issue opened on December 3 and closed on December 5, 2025.
Continue reading
The Fourth IBA India Litigation and ADR Symposium concluded with a panel discussion on privacy and the new Digital Personal Data Protection Act as well as a debate on whether social media was the only reliable source of news.
Continue reading
Khaitan & Co appoints Dr. Vimal Choudhary as Chief Operating Officer, bringing over 23 years of global consulting and strategy experience to drive the Firm’s growth and digital transformation.
Continue reading
The session explored how artificial intelligence is reshaping intellectual property law, from data-scraping and authorship debates to personality rights and deepfake misuse. The discussion underscored the need for clearer safeguards, transparency obligations and balanced governance frameworks as AI accelerates real-world disputes.
Continue reading
Cyril Amarchand Mangaldas advised Sheela Foam Limited on further investment in Furlenco via preferential issue and structuring investor rights in the funding round.
Continue reading
Lakshmikumaran & Sridharan advised Sai Parenteral’s Limited and its Singapore arm on the cross-border acquisition of 74.6% stake in Noumed Pharmaceuticals Pty Ltd, Australia.
Continue reading
Cyril Amarchand Mangaldas advised Serum Institute on the proposed sale of its stake in Biocon Biologics to Biocon and the simultaneous subscription of shares in Biocon Limited through a share swap transaction valued at ₹2,250 crore. The deal marks a significant restructuring in India’s biopharmaceutical sector.
Continue reading
The second day of the Fourth IBA India Litigation and ADR Symposium, held on 6th December 2025, traversed various emerging topics in the legal field such as developments in arbitration law, emerging issues in IPR and AI, privacy, AI in dispute resolution, and more.
Continue reading
Khaitan & Co advised Viatris on the USD 815 million sale of its stake in Biocon Biologics to Biocon via cash payment and preferential share allotment.
Continue reading
Fox & Mandal successfully defended Shalimar before the Calcutta High Court in a passing-off action, securing protection for its distinctive trade dress and packaging.
Continue reading
Cyril Amarchand Mangaldas advised Swiss Parenterals Limited and its promoter on the sale of the remaining 30% stake to Eris Lifesciences Limited through a preferential allotment deal worth ₹423.30 crore.
Continue reading